BlackRock, Inc. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Syros Pharmaceuticals, Inc. SYRS |
BlackRock Inc. BLK |
152,431 2.400% |
-270,796 (-63.98%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
BlackRock Inc. BLK |
423,227 6.800% |
90,671 (+27.26%) |
Filing |
| 2021-02-01 08:23 am Purchase |
2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
BlackRock Inc. BLK |
332,556 7.300% |
46,215 (+16.14%) |
Filing |